[144] Centessa Pharmaceuticals plc American SEC Filing
Centessa Pharmaceuticals plc (CNTA) filing a Form 144 notifies a proposed sale of 6,000 common shares to be offered through UBS Financial Services on Nasdaq with an aggregate market value of $103,380.00. The filer reports those shares were acquired the same day, 08/15/2025, by exercising stock options and paid in cash.
The filing also discloses prior sales by the same person, Iqbal Hussain: 12,000 shares sold on 06/24/2025 for $168,218.40 and 6,000 shares sold on 07/15/2025 for $89,566.80. The notice affirms no undisclosed material nonpublic information applies to the seller.
Centessa Pharmaceuticals plc (CNTA) ha presentato un Form 144 per notificare la proposta vendita di 6.000 azioni ordinarie tramite UBS Financial Services sul Nasdaq, per un valore complessivo di $103.380,00. Il dichiarante indica che queste azioni sono state acquisite lo stesso giorno, il 15/08/2025, esercitando opzioni su azioni e pagando in contanti.
La comunicazione riporta inoltre vendite precedenti da parte della stessa persona, Iqbal Hussain: 12.000 azioni vendute il 24/06/2025 per $168.218,40 e 6.000 azioni vendute il 15/07/2025 per $89.566,80. La dichiarazione conferma che al venditore non si applicano informazioni riservate materialmente rilevanti non divulgate.
Centessa Pharmaceuticals plc (CNTA) present贸 un Form 144 para notificar la propuesta de venta de 6.000 acciones ordinarias a ofrecerse a trav茅s de UBS Financial Services en el Nasdaq, con un valor agregado de $103,380.00. El declarante informa que esas acciones fueron adquiridas el mismo d铆a, 15/08/2025, mediante el ejercicio de opciones sobre acciones y pagadas en efectivo.
La presentaci贸n tambi茅n revela ventas anteriores de la misma persona, Iqbal Hussain: 12.000 acciones vendidas el 24/06/2025 por $168,218.40 y 6.000 acciones vendidas el 15/07/2025 por $89,566.80. La notificaci贸n afirma que no existen informaciones materiales no p煤blicas no divulgadas aplicables al vendedor.
Centessa Pharmaceuticals plc (CNTA)電� Form 144毳� 鞝滌稖頃橃棳 UBS Financial Services毳� 韱淀暣 雮橃姢雼レ棎靹� 齑濎暋 $103,380.00鞐� 頃措嫻頃橂姅 6,000 氤错喌欤� 毵る弰毳� 鞝滌晥頄堨潓鞚� 韱奠頄堨姷雼堧嫟. 鞝滌稖鞛愲姅 頃措嫻 欤检嫕鞚� 臧欖潃 雮犾澑 2025-08-15鞐� 鞀ろ啞鞓奠厴鞚� 頄夓偓頃橁碃 順勱笀鞙茧 歆�旮夗晿鞐� 旆摑霅橃棃雼り碃 氤搓碃頄堨姷雼堧嫟.
頃措嫻 鞝滌稖靹滌棎電� 霃欖澕鞚� Iqbal Hussain鞚� 鞚挫爠 毵る弰 雮挫棴霃� 瓿店皽霅橃柎 鞛堨姷雼堧嫟: 12,000欤茧ゼ 2025-06-24鞐� $168,218.40鞐� 毵る弰頄堦碃, 6,000欤茧ゼ 2025-07-15鞐� $89,566.80鞐� 毵る弰頄堨姷雼堧嫟. 韱奠電� 韺愲Г鞛愳棎瓴� 瓿店皽霅橃 鞎婌潃 欷戩殧 牍勱车臧� 鞝曤炒臧� 鞝侅毄霅橃 鞎婌潓鞚� 頇曥澑頃╇媹雼�.
Centessa Pharmaceuticals plc (CNTA) a d茅pos茅 un Form 144 pour notifier la vente propos茅e de 6 000 actions ordinaires qui seront offertes via UBS Financial Services sur le Nasdaq, pour une valeur totale de 103 380,00 $. Le d茅clarant indique que ces actions ont 茅t茅 acquises le m锚me jour, le 15/08/2025, par l'exercice d'options sur actions et pay茅es en esp猫ces.
Le d茅p么t r茅v猫le 茅galement des ventes ant茅rieures par la m锚me personne, Iqbal Hussain听: 12 000 actions vendues le 24/06/2025 pour 168 218,40 $ et 6 000 actions vendues le 15/07/2025 pour 89 566,80 $. L'avis affirme qu'aucune information mat茅rielle non publique non divulgu茅e ne s'applique au vendeur.
Centessa Pharmaceuticals plc (CNTA) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 6.000 Stammaktien 眉ber UBS Financial Services an der Nasdaq mit einem Gesamtwert von $103.380,00 ank眉ndigt. Der Melder gibt an, dass diese Aktien am selben Tag, dem 15.08.2025, durch Aus眉bung von Aktienoptionen erworben und bar bezahlt wurden.
Die Meldung legt au脽erdem fr眉here Verk盲ufe derselben Person, Iqbal Hussain, offen: 12.000 Aktien verkauft am 24.06.2025 蹿眉谤 $168.218,40 und 6.000 Aktien verkauft am 15.07.2025 蹿眉谤 $89.566,80. Die Mitteilung best盲tigt, dass beim Verk盲ufer keine nicht offengelegten, bedeutenden nicht-枚ffentlichen Informationen vorliegen.
- None.
- None.
Insights
TL;DR Insider exercised options and is selling a small block of shares; transactions are routine and immaterial to company capitalization.
The 6,000-share proposed sale represents a very small fraction of the issuer's reported outstanding shares (134,073,436), so dilution or market impact is negligible. The acquisition via option exercise and immediate planned sale is a common liquidity action. Prior sales totaling 18,000 shares in the past three months show ongoing portfolio cashing but are minor relative to outstanding shares. No financial results or governance changes are disclosed.
TL;DR The Form 144 is a standard compliance notice tied to option exercise and planned resale; it includes the seller's required certifications.
The filer certifies absence of undisclosed material information and, if applicable, reliance on a trading plan is noted though no plan date is provided. The record lists broker, acquisition method, payment type, and recent sales history, fulfilling disclosure obligations. There are no governance issues, regulatory actions, or material events disclosed in this notice.
Centessa Pharmaceuticals plc (CNTA) ha presentato un Form 144 per notificare la proposta vendita di 6.000 azioni ordinarie tramite UBS Financial Services sul Nasdaq, per un valore complessivo di $103.380,00. Il dichiarante indica che queste azioni sono state acquisite lo stesso giorno, il 15/08/2025, esercitando opzioni su azioni e pagando in contanti.
La comunicazione riporta inoltre vendite precedenti da parte della stessa persona, Iqbal Hussain: 12.000 azioni vendute il 24/06/2025 per $168.218,40 e 6.000 azioni vendute il 15/07/2025 per $89.566,80. La dichiarazione conferma che al venditore non si applicano informazioni riservate materialmente rilevanti non divulgate.
Centessa Pharmaceuticals plc (CNTA) present贸 un Form 144 para notificar la propuesta de venta de 6.000 acciones ordinarias a ofrecerse a trav茅s de UBS Financial Services en el Nasdaq, con un valor agregado de $103,380.00. El declarante informa que esas acciones fueron adquiridas el mismo d铆a, 15/08/2025, mediante el ejercicio de opciones sobre acciones y pagadas en efectivo.
La presentaci贸n tambi茅n revela ventas anteriores de la misma persona, Iqbal Hussain: 12.000 acciones vendidas el 24/06/2025 por $168,218.40 y 6.000 acciones vendidas el 15/07/2025 por $89,566.80. La notificaci贸n afirma que no existen informaciones materiales no p煤blicas no divulgadas aplicables al vendedor.
Centessa Pharmaceuticals plc (CNTA)電� Form 144毳� 鞝滌稖頃橃棳 UBS Financial Services毳� 韱淀暣 雮橃姢雼レ棎靹� 齑濎暋 $103,380.00鞐� 頃措嫻頃橂姅 6,000 氤错喌欤� 毵る弰毳� 鞝滌晥頄堨潓鞚� 韱奠頄堨姷雼堧嫟. 鞝滌稖鞛愲姅 頃措嫻 欤检嫕鞚� 臧欖潃 雮犾澑 2025-08-15鞐� 鞀ろ啞鞓奠厴鞚� 頄夓偓頃橁碃 順勱笀鞙茧 歆�旮夗晿鞐� 旆摑霅橃棃雼り碃 氤搓碃頄堨姷雼堧嫟.
頃措嫻 鞝滌稖靹滌棎電� 霃欖澕鞚� Iqbal Hussain鞚� 鞚挫爠 毵る弰 雮挫棴霃� 瓿店皽霅橃柎 鞛堨姷雼堧嫟: 12,000欤茧ゼ 2025-06-24鞐� $168,218.40鞐� 毵る弰頄堦碃, 6,000欤茧ゼ 2025-07-15鞐� $89,566.80鞐� 毵る弰頄堨姷雼堧嫟. 韱奠電� 韺愲Г鞛愳棎瓴� 瓿店皽霅橃 鞎婌潃 欷戩殧 牍勱车臧� 鞝曤炒臧� 鞝侅毄霅橃 鞎婌潓鞚� 頇曥澑頃╇媹雼�.
Centessa Pharmaceuticals plc (CNTA) a d茅pos茅 un Form 144 pour notifier la vente propos茅e de 6 000 actions ordinaires qui seront offertes via UBS Financial Services sur le Nasdaq, pour une valeur totale de 103 380,00 $. Le d茅clarant indique que ces actions ont 茅t茅 acquises le m锚me jour, le 15/08/2025, par l'exercice d'options sur actions et pay茅es en esp猫ces.
Le d茅p么t r茅v猫le 茅galement des ventes ant茅rieures par la m锚me personne, Iqbal Hussain听: 12 000 actions vendues le 24/06/2025 pour 168 218,40 $ et 6 000 actions vendues le 15/07/2025 pour 89 566,80 $. L'avis affirme qu'aucune information mat茅rielle non publique non divulgu茅e ne s'applique au vendeur.
Centessa Pharmaceuticals plc (CNTA) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 6.000 Stammaktien 眉ber UBS Financial Services an der Nasdaq mit einem Gesamtwert von $103.380,00 ank眉ndigt. Der Melder gibt an, dass diese Aktien am selben Tag, dem 15.08.2025, durch Aus眉bung von Aktienoptionen erworben und bar bezahlt wurden.
Die Meldung legt au脽erdem fr眉here Verk盲ufe derselben Person, Iqbal Hussain, offen: 12.000 Aktien verkauft am 24.06.2025 蹿眉谤 $168.218,40 und 6.000 Aktien verkauft am 15.07.2025 蹿眉谤 $89.566,80. Die Mitteilung best盲tigt, dass beim Verk盲ufer keine nicht offengelegten, bedeutenden nicht-枚ffentlichen Informationen vorliegen.
FAQ
What does the Form 144 for CNTA disclose about the proposed sale?
How were the shares being sold on 08/15/2025 acquired?
Who is the seller named in recent transactions?
How many outstanding shares does Centessa report in the filing?
Does the filer attest to possession of undisclosed material information?
